Prognostic Value of KELIM Score and Inflammatory Markers in Ovarian Cancer

Integrative Prognostic Value of Inflammatory Markers and KELIM Score in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07678008

Enrollment

Registered

2026-07-01

Start date

2026-06-01

Completion date

2027-02-01

Last updated

2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Ovarian Cancer (Stage III or IV) After Neoadjuvant Chemotherapy, High-grade Serous Ovarian Carcinoma

Keywords

KELIM Score, Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR), Neoadjuvant Chemotherapy

Brief summary

This is a retrospective observational study to evaluate the integrative prognostic value of inflammatory markers, specifically the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), alongside the CA-125 Elimination rate constant K (KELIM) score in advanced ovarian cancer patients. The study includes patients with advanced serous ovarian cancer (stage III or IV) who received neoadjuvant platinum-based chemotherapy followed by interval debulking surgery at Sohag University Hospital and Sohag Cancer Center between 2022 and 2025. The primary objective is to evaluate how well these biomarkers predict survival outcomes, including progression-free survival (PFS) and overall survival (OS). Additionally, the study aims to assess their significance in predicting the success of complete versus incomplete cytoreductive surgery following neoadjuvant chemotherapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Female patients aged \\ge 18 years old., Histologically confirmed advanced epithelial ovarian cancer (High-Grade Serous Ovarian Carcinoma), Stage III or IV. Patients who received platinum-based neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) at Sohag University Hospital or Sohag Cancer Center between 2022 and 2025. Available complete medical records, including pre-treatment baseline CBC (for NLR and PLR calculation) and longitudinal CA-125 levels (for KELIM score estimation).

Exclusion criteria

Patients with non-epithelial ovarian tumors (e.g., germ cell tumors, sex cord-stromal tumors). Patients who underwent primary debulking surgery (PDS) before receiving chemotherapy. Patients with concurrent active malignancies or a history of other cancers within the past 5 years. Patients with active systemic inflammatory diseases, hematological disorders, or severe infections at baseline that could interfere with baseline inflammatory markers (NLR/PLR). Incomplete or missing clinical, surgical, or follow-up data. \-

Design outcomes

Primary

Measure	Time frame	Description
Progression-Free Survival (PFS)	From the date of diagnosis up to 4 years (assessed using retrospective medical records of patients treated between 2022 and 2025).	Evaluation of the prognostic value of baseline neutrophil lymphocyte ratio, platelet lymphocyte ratio, and CA 125 KELIM score in predicting progression-free survival in locally advanced ovarian cancer patients receiving platinum-based neoadjuvant chemotherapy followed by interval debulking surgery. PFS is calculated as the time from the date of diagnosis to the date of first documented clinical or radiological disease progression, or death from any cause.
Overall Survival (OS)	From the date of diagnosis up to 4 years (assessed using retrospective medical records of patients treated between 2022 and 2025).	Evaluation of the prognostic value of baseline neutrophil lymphocyte ratio, platelet lymphocyte ratio, and CA 125 KELIM score in predicting overall survival in locally advanced ovarian cancer patients receiving platinum-based neoadjuvant chemotherapy followed by interval debulking surgery. OS is calculated as the time from the date of diagnosis to the date of death from any cause.

Secondary

Measure	Time frame	Description
Completeness of Interval Cytoreductive Surgery	At the time of interval debulking surgery (typically performed after 3 to 6 cycles of neoadjuvant chemotherapy).	Evaluation of the significance of baseline neutrophil lymphocyte ratio, platelet lymphocyte ratio, and CA 125 KELIM score in predicting surgical outcomes. The success of the interval debulking surgery will be categorized based on the presence of residual tumor into complete cytoreduction (no macroscopically visible tumor) versus incomplete cytoreduction following neoadjuvant chemotherapy.

Countries

Egypt

Outcome results